Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-06-19

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Annual General Meeting

Time:2025-06-06

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Proposed Acquisition of Equity Interests in Vietnam IMP by Controlled Subsidiary Livzon Group

Time:2025-05-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Aripiprazole Microspheres for Injection

Time:2025-05-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2025 First Extraordinary General Meeting

Time:2025-05-09

Ad hoc announcement pursuant to Art. 53 LR -JCARE 2025 First Quarterly Report

Time:2025-04-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Anuual General Meeting

Time:2025-04-24

Ad hoc announcement pursuant to Art. 53 LR -JCARE 2024 Annual Report

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR -JOINCARE Announcement on Re-appointment of The Auditor

Time:2025-04-07

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on the Resignation and Replacement of an Independent Director

Time:2025-04-07

< 1234...12 >